DAX24.129 -0,1%Est505.883 -0,2%MSCI World4.343 -0,1%Top 10 Crypto9,8700 -1,2%Nas24.817 +1,6%Bitcoin66.227 -1,2%Euro1,1719 +0,3%Öl105,1 -0,9%Gold4.723 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SAP 716460 Rheinmetall 703000 Siemens Energy ENER6Y Infineon 623100 Intel 855681 NVIDIA 918422 Deutsche Telekom 555750 Lufthansa 823212 AMD (Advanced Micro Devices) 863186 Amazon 906866 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Allianz 840400 TUI TUAG50
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen: Gute Laune bei Tech-Aktien -- DAX geht schwächer ins Wochenende -- SAP-Gewinn steigt stärker als erwartet -- Intel kehrt in die Gewinnzone zurück -- Tesla, Commerzbank, Newmont im Fokus
Top News
Silberpreis, Goldpreis & Co. aktuell: So steht es am Freitagabend um die Kurse der Rohstoffe Silberpreis, Goldpreis & Co. aktuell: So steht es am Freitagabend um die Kurse der Rohstoffe
SAP-Aktie springt an: Gewinn steigt stärker als erwartet - Umsatz ebenfalls höher SAP-Aktie springt an: Gewinn steigt stärker als erwartet - Umsatz ebenfalls höher
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
109,25 EUR -1,45 EUR -1,31 %
STU
128,16 USD -2,06 USD -1,58 %
BTT
finanzen.net zero
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.11,27 Mrd. EUR

KGV30,38Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in December
PR NewswireNeurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in November
PR NewswireNeurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
PR NewswireNeurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
PR NewswireNeurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
PR NewswireNeurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in September
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
PR NewswireNeurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
PR NewswireNeurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
PR NewswireNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR NewswireNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in June
PR NewswireNeurocrine Biosciences Announces CEO Succession Plan
PR NewswireNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH a...
PR NewswireNeurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZ...
PR NewswireNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
PR NewswireNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
PR NewswireNeurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
PR NewswireNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insuffic...
PR NewswireNeurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
PR NewswireNeurocrine Biosciences Reports First Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.